Skip To Main Content
David Rodbard on Muck Rack

David Rodbard

Potomac
As seen in: Wiley Online Library, JAMA (The Journal of the American Medical Association), Mary Ann Liebert, Inc., Diabetes Care Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Characterizing insulin dosing behaviour and glycaemic excursions: Development of metrics using connected insulin pen and continuous glucose monitoring

|
By Howard A. Wolpert, David Rodbard, Jie Xue
| Wiley Online Library Verified
1 INTRODUCTION Despite advances in glucose measurement technology and improved insulins, about 50% of people with diabetes using insulin therapy fail to reach recommended glycaemic goals.1 The reasons for failure to meet glycaemic goals are multifactorial but include the complexity of insulin regimens and the suboptimal use of bolus insulin for anticipated food intake and to correct hyperglycaemia.
Open in Who Shared Issue with article?

Standardizing Reporting of Glucose and Insulin Data for Patients on Multiple Daily Injections Using Connected Insulin Pens and Continuous Glucose Monitoring

|
By David Rodbard, Satish K. Garg
| Mary Ann Liebert, Inc.
Introduction The number of insulin-requiring patients with diabetes continues to increase and is a major public health concern worldwide.1,2 Improvements in insulin analogues and introduction of technologies such as continuous glucose monitors (CGMs), insulin pumps, and development of automated insulin delivery systems have greatly facilitated diabetes management.1–3 The majority of people using insulin pumps have type 1 diabetes and are located primarily in the United States and western...
Open in Who Shared Issue with article?

Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study*

|
By Thomas C. Blevins, Wendy Lane, David Rodbard, Dana Sindelar
| Mary Ann Liebert, Inc.
Introduction In people with type 2 diabetes (T2D) who remain poorly controlled on high doses of insulin, U-500R insulin has been shown to effectively lower A1C.1 The EValuating U-500R Infusion Versus Injection in Type 2 Diabetes Mellitus (VIVID) study was the first large randomized trial comparing treatment with U-500R by continuous subcutaneous insulin infusion (CSII) with a specifically designed pump to U-500R by multiple daily injections (MDI).
Open in Who Shared Issue with article?
See all 6 articles